Feb 5, 2021
AUSTIN, Texas, Feb. 5, 2021 (SEND2PRESS NEWSWIRE) Kalyagen™, along with the Sociedad Espanola de Medicina Regenerativa y Terapia Celular (the Spanish Society of Regenerative Medicine and Cell Therapy ), is pleased to announce the launch of a multicenter clinical trial, The Effect of Stemregen and Adipose Stroma Vascular Fraction (SVF) Either Individually or in Combination in Patient With Heart Failure, to evaluate the use of stem cell therapies in patients suffering from heart failure.
EXPLORE TOPICS
Kalyagen™ Announces Launch of Clinical Trial to Evaluate STEMREGEN® and Stem Cells for Advanced Heart Failure Patients greensburgdailynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from greensburgdailynews.com Daily Mail and Mail on Sunday newspapers.
(AUSTIN, Texas) NEWS: Kalyagen™, along with the Sociedad Espanola de Medicina Regenerativa y Terapia Celular (the “Spanish Society of Regenerative Medicine and Cell Therapy”), is pleased to announce the launch of a multicenter clinical trial, “The Effect of Stemregen and Adipose Stroma Vascular Fraction (SVF) Either Individually or in Combination in Patient With Heart Failure,” to evaluate the use of stem cell therapies in patients suffering from heart failure. STEMREGEN® is a natural stem cell enhancer documented to increase the number of circulating stem cells by stimulating Endogenous Stem Cell Mobilization (ESCM).
“The link between a lower number of circulating stem cells and the development of age-related diseases has been well studied with numerous degenerative conditions, including diabetes, cardiovascular diseases, atherosclerosis, Alzheimer’s disease, rheumatoid arthritis, pulmonary diseases, erectile dysfunction, and kidney disease,” said Christian Drape